Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Better Buy: Eli Lilly vs. Pfizer

TheMotleyFool

0 0

Better Buy: Eli Lilly vs. PfizerPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png

Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) have been two of the best-performing big pharma stocks over the past decade. Nonetheless, these two pharma titans have both run into serious trouble this year due to a mix of patent woes, headwinds from restructuring, and the raging prescription drug-pricing debate in the United States.

Which of these top pharma stocks is better positioned to rebound in 2020? To answer this all-important question, let's take a look at their respective product portfolios, late-stage clinical pipelines, and near-term growth prospects.

Image source: Getty Images.

Source Fool.com

Like: 0

LLY

Teilen